Brief: Chimeric Therapeutics Says Core-Nk + Vactosertib Phase 1B Trial Temporarily Suspended
12/11/2025 23:45
Nov 13 (Reuters) - Chimeric Therapeutics Ltd CHM.AX: CHM CORE NK COMBINATION PHASE 1B TRIAL UPDATE CORE-NK + VACTOSERTIB PHASE 1B TRIAL TEMPORARILY SUSPENDED Further company coverage: CHM.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chimeric Therapeutics
See all newsBrief: Chimeric Therapeutics Says Phillip Hains Appointed Interim Chairman
Brief: Chimeric Therapeutics Posts Prelim Loss For Year Of A$18.8 MLN
Brief: Chimeric Therapeutics Intends To Enter Negotiations With Its Creditors
Brief: Chimeric Therapeutics Seeks Trading Halt
Australia's Chimeric Therapeutics rises on positive data for its cell therapy clinical trial